Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

217 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-01

Study Completion Date

2018-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU.

Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.

Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery

NCT00464763

Delirium

WITHDRAWN PHASE3

Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients

NCT02509949

Postoperative Delirium After Living Donor Renal Transplantation

UNKNOWN PHASE4

Dexmedetomidine After Cardiac Surgery for Prevention of Delirium

NCT03477344

ICU Delirium

COMPLETED PHASE3

Dexmedetomidine and Delirium in Patients After Cardiac Surgery

NCT02267538

Delirium C.Surgical Procedure; Cardiac Postoperative Complications

COMPLETED PHASE4

Dexmedetomidine on Postoperative Delirium and Quality of Recovery in Geriatric Patients

NCT01283412

Delirium, Postoperative

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal saline

same infusion rate as experimental group (dexmedetomidine)

Group Type PLACEBO_COMPARATOR

placebo control

Intervention Type DRUG

placebo

dexmedetomidine

0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.

Group Type EXPERIMENTAL

Precedex

Intervention Type DRUG

infusion of 0.1mcg/kg/hr of precedex

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Precedex

infusion of 0.1mcg/kg/hr of precedex

Intervention Type DRUG

placebo control

placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

0.9% saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantation

Exclusion Criteria

* Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No